financenews

Ferrari N.V. Releases Periodic Report on Buyback Program

Charmingly eccentric, full of personality, and designed for maximum reader engagement Ferrari Purchases Additional Common Shares Maranello (Italy), September 23, 2024 Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on June 28, 2024, as the fifth tranche of the multi-year…

Read More

Charmingly Eccentric: Zefiro Methane Corp Appoints Richard Walker as Chief Technology Officer

Charmingly Eccentric: A Look into Zefiro’s Latest Game-Changing Move Meet Walker: The Tech Strategist with a Flair for Innovation With over thirty years of experience in enterprise technology strategy, Walker will be tasked with integrating a host of innovative solutions – including artificial intelligence – throughout Zefiro’s environmental remediation and carbon markets divisions. Walker has…

Read More

Crude Oil, Hang Seng, USD/CNH, and Cyclicals: The Latest Buzz in the World of Trading (Plus Some Soft Landing Hopes!)

Have You Ever Wondered How Technical Factors Influence Market Movements? Deciphering the Complexities of Price Action For all the fundamental reasons put forward to explain their day-to-day gyrations, one look at price action suggests technical factors are arguably just as important in determining movements in the likes of Hong Kong’s Hang Seng, USD/CNH and crude…

Read More

Bitcoin Bull Arthur Hayes Set to Acquire Iggy Azalea’s Mother Token: A Cryptocurrency Market Update

Arthur Hayes Shows Interest in Iggy Azalea’s Memecoin Mother Iggy What Happened Arthur Hayes, the co-founder of cryptocurrency exchange BitMEX, recently signaled interest in Australian rapper Iggy Azalea’s memecoin Mother Iggy (MOTHER). In a post late Sunday night, Hayes highlighted how Bitcoin (CRYPTO: BTC) remained stable over the weekend while the Japanese Yen weakened following…

Read More

Unlocking the Power of BA3362: A Revolutionary Nectin-4 x CD3 T-Cell Engaging Antibody – BioAtla and Context Therapeutics Join Forces in Exclusive Worldwide License Agreement

The Future of Cancer Treatment: A Collaboration Between BioAtla and Context Therapeutics An Exciting Partnership News broke today about a groundbreaking collaboration between BioAtla, a leading biotechnology company, and Context Therapeutics Inc., a biopharmaceutical company focused on T cell engaging bispecific antibodies. This partnership entails Context Therapeutics acquiring exclusive development and commercialization rights to BioAtla’s…

Read More

XOMA Royalty Announces Quarterly Dividends for Preferred Stock

XOMA Royalty Corporation Announces Dividend Declaration Emeryville, Calif., September 23, 2024 XOMA Royalty Corporation (Nasdaq: XOMA) has made an exciting announcement today regarding cash dividends for holders of XOMA’s Series A and Series B Cumulative Preferred Stock. Details of Dividend Declaration: The Board of Directors has authorized the following cash dividends: Holders of the 8.625%…

Read More